Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Targeted Covalent Pentafluorobenzene Sulfonamide-Based Afatinib Drug for Treating Breast Cancer

EF 2019-20

Résumé
"Breast cancer is a common malignancy in Canadian women accounting for approximately 14 deaths daily. Although there have been several advancements in treatments, current drugs are plagued by resistance mechanisms and off-target effects which leads to higher dosing regimens and unpleasant side effects. This is particularly important for a class of drugs, termed covalent therapeutics. Covalent therapeutics, unlike conventional drugs, are very reactive molecules and bind irreversibly to their target which halts its normal function. Although this is a desirable objective in a cancer cell, since covalent therapeutics are very reactive, they can also bind irreversibly to non-cancer targets, which contributes to patient side-effects and toxicity. We have recently developed new technology that allows us to fine-tune the reactivity of a covalent therapeutic thereby limiting off target effects. We are aiming to apply this technology to current breast cancer treatments, such as the current breast-cancer drug afatinib. We will synthesize a large library of afatinib-like drugs based on our new technology. We will use state-of-the-art computer simulations and quantum mechanical models, to predict the reactivity of the different compounds. We will test these compounds against breast-cancer cells in an isolated petri dish to determine their potency and effectiveness. In this strategy, we will gradually funnel our large library of compounds to generate a small number of the top hits with convincing drug profiles. Since afatinib is currently dosed with other drug combinations for breast cancer, we hope this research seeks to find a treatment that not only improve the quality of life for Canadian women but also extend the life span of women diagnosed with breast cancer."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428860
Name
Hekmat Merna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeted Covalent Pentafluorobenzene Sulfonamide-Based Afatinib Drug for Treating Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Afatinib Drug; Biophysical Assay; Breast Cancer; Covalent Inhibitors; Drug Discovery; Electrophilic Tuning; Epidermal Growth Factor Receptor; Kinases; Nucleophilic Aromatic Substitution; Pentafluorobenzene Sulfonamide
Abstract
"Breast cancer is a common malignancy in Canadian women accounting for approximately 14 deaths daily. Although there have been several advancements in treatments, current drugs are plagued by resistance mechanisms and off-target effects which leads to higher dosing regimens and unpleasant side effects. This is particularly important for a class of drugs, termed covalent therapeutics. Covalent therapeutics, unlike conventional drugs, are very reactive molecules and bind irreversibly to their target which halts its normal function. Although this is a desirable objective in a cancer cell, since covalent therapeutics are very reactive, they can also bind irreversibly to non-cancer targets, which contributes to patient side-effects and toxicity. We have recently developed new technology that allows us to fine-tune the reactivity of a covalent therapeutic thereby limiting off target effects. We are aiming to apply this technology to current breast cancer treatments, such as the current breast-cancer drug afatinib. We will synthesize a large library of afatinib-like drugs based on our new technology. We will use state-of-the-art computer simulations and quantum mechanical models, to predict the reactivity of the different compounds. We will test these compounds against breast-cancer cells in an isolated petri dish to determine their potency and effectiveness. In this strategy, we will gradually funnel our large library of compounds to generate a small number of the top hits with convincing drug profiles. Since afatinib is currently dosed with other drug combinations for breast cancer, we hope this research seeks to find a treatment that not only improve the quality of life for Canadian women but also extend the life span of women diagnosed with breast cancer."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hekmat, Merna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~